GSK plc

GSK plc Tangible Book Value per Share

The Tangible Book Value per Share of GSK plc (GSK.L) as of Nov 11, 2026 is 2.27 GBP. In the previous year, Tangible Book Value per Share was -2.14 GBP — a change of -206.04% (higher).

Tangible Book Value per Share

2.27GBP

YoY

-206.04%

Last updated:

Tangible Book Value per Share of GSK plc is 2025 2.27 GBP. Tangible Book Value per Share of GSK plc was 2024 -2.14 GBP. It decreases by -206.04% higher compared to the previous year.

The GSK plc Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
-4.67 GBP
Jan 1, 2019
-7.31 GBP
Jan 1, 2020
-6.27 GBP
Jan 1, 2021
-6.21 GBP
Jan 1, 2022
-2.62 GBP
Jan 1, 2023
-2.00 GBP
Jan 1, 2024
-2.14 GBP
Jan 1, 2025
2.27 GBP
The GSK plc Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
2.27GBP-206.04%
-2.14GBP+7.22%
-2.00GBP-23.54%
-2.62GBP-57.91%
-6.21GBP-1.00%
-6.27GBP-14.21%
-7.31GBP+56.75%
-4.67GBP-17.78%
-5.68GBP-1.07%
-5.74GBP+41.25%
-4.06GBP+114.88%
-1.89GBP+41.36%
-1.34GBP-24.74%
-1.78GBP+154.51%
-0.70GBP+11.56%
-0.63GBP+111.03%
-0.30GBP+3,750.65%
-0.01GBP-101.12%
0.69GBP-26.02%
0.93GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Tangible Book Value per Share of GSK plc is 2.27 GBP in 2025.

Tangible Book Value per Share of GSK plc changed from -2.14 GBP to 2.27 GBP, representing a -206.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share GSK plc since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GSK plc

All Key Metrics — GSK plc